Affinivax
A clinical stage biopharmaceutical company pioneering the development of a novel class of vaccines designed to induce a broad and robust protective immune response to both disease-relevant polysaccharides and disease-relevant proteins in a single vaccine.
Affinivax’s lead vaccine candidate, ASP3772, is a Streptococcus pneumoniae vaccine that is being co-developed in collaboration with Japanese drugmaker Astellas.
ASP3772 includes 24 pneumococcal polysaccharides, more than any other vaccine on the market or in clinical trials today, as well as two conserved pneumococcal proteins. This candidate was observed to be safe and highly immunogenic in a Phase I study in adults aged 18 to 64.
In January 2021, Affinivax announced that it had closed a $226 million Series C financing to raise funds for advancing its pipeline of vaccines.
Latest Affinivax News & Features
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze